Multiple functional strategies for amplifying sensitivity of amperometric immunoassay for tumor markers: A review

Tang, Zhongxue; Ma, Zhanfang

doi:10.1016/j.bios.2017.06.041

Cited by 96 publications

(28 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is a sensitive EAT that utilizes an applied potential for inducing oxidation or reduction of the target analyte and the response is observed as a change of current signal with respect to time and the analyte concentration [101]. It is one of the most popular EATs because it offers sensitive detection and is very simple to use [101,102]. The LOD of the amperometric technique is in the range of 10 −5 M [103].…”

Section: Amperometric Techniquementioning

confidence: 99%

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

et al. 2020

View full text Add to dashboard Cite

With the rise in public health awareness, research on point-of-care testing (POCT) has significantly advanced. Electrochemical biosensors (ECBs) are one of the most promising candidates for the future of POCT due to their quick and accurate response, ease of operation, and cost effectiveness. This review focuses on the use of metal nanoparticles (MNPs) for fabricating ECBs that has a potential to be used for POCT. The field has expanded remarkably from its initial enzymatic and immunosensor-based setups. This review provides a concise categorization of the ECBs to allow for a better understanding of the development process. The influence of structural aspects of MNPs in biocompatibility and effective sensor design has been explored. The advances in MNP-based ECBs for the detection of some of the most prominent cancer biomarkers (carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), Herceptin-2 (HER2), etc.) and small biomolecules (glucose, dopamine, hydrogen peroxide, etc.) have been discussed in detail. Additionally, the novel coronavirus (2019-nCoV) ECBs have been briefly discussed. Beyond that, the limitations and challenges that ECBs face in clinical applications are examined and possible pathways for overcoming these limitations are discussed.

show abstract

Section: Amperometric Techniquementioning

confidence: 99%

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This feature allows for immunoassays to be coupled to a range of different detection methods, including radiometric, fluorescent, colorimetric, chemiluminescent, non-labelled (light scattering) and electrochemical detection [ 4 , 6 ]. Detection can be further enhanced using enzymatic, polymerase chain reaction (PCR), liposome and nanomaterial-based signal amplification strategies [ [7] , [8] , [9] ].…”

Section: Introductionmentioning

confidence: 99%

Conjugating immunoassays to mass spectrometry: Solutions to contemporary challenges in clinical diagnostics

Stevens

Pukala

2020

TrAC Trends in Analytical Chemistry

View full text Add to dashboard Cite

Developments in immunoassays and mass spectrometry have independently influenced diagnostic technology. However, both techniques possess unique strengths and limitations, which define their ability to meet evolving requirements for faster, more affordable and more accurate clinical tests. In response, hybrid techniques, which combine the accessibility and ease-of-use of immunoassays with the sensitivity, high throughput and multiplexing capabilities of mass spectrometry are continually being explored. Developments in antibody conjugation methodology have expanded the role of these biomolecules to applications outside of conventional colorimetric assays and histology. Furthermore, the range of different mass spectrometry ionisation and analysis technologies has enabled its successful adaptation as a detection method for numerous clinically relevant immunological assays. Several recent examples of combined mass spectrometry-immunoassay techniques demonstrate the potential of these methods as improved diagnostic tests for several important human diseases. The present challenges are to continue technological advancements in mass spectrometry instrumentation and develop improved bioconjugation methods, which can overcome their existing limitations and demonstrate the clinical significance of these hybrid approaches.

show abstract

“…All of these assays depend on the reaction between antibodies and application-specific antigens. Among these methods, label-free electrochemical immunosensors have generated substantial interest due to their relatively high sensitivity, cost effectiveness, rapid detection, and lack of need for a secondary antibody [16,17,18].…”

Section: Introductionmentioning

confidence: 99%

A Label-Free Electrochemical Immunosensor for Detection of the Tumor Marker CA242 Based on Reduced Graphene Oxide-Gold-Palladium Nanocomposite

Zheng

Zhang

et al. 2019

Nanomaterials

View full text Add to dashboard Cite

As a tumor marker, carbohydrate antigen 24-2 (CA242) is a highly accurate and specific diagnostic indicator for monitoring pancreatic and colorectal cancers. The goal of this study was to create a novel label-free electrochemical immunosensor using a nanocomposite glassy carbon electrode for the detection of CA242. Graphene oxide (GO) and polyvinyl pyrrolidone were chosen as the dopants for the preparation of a high-performance reduced-GO-gold-palladium (rGO-Au-Pd) nanocomposite. RGO-Au-Pd was characterized using X-ray diffraction and transmission electron microscopy, revealing that the material exhibited superior electrochemical redox activity and electron transfer ability. The effects of the synthesis method, material concentration, reduction cycle, and pH were investigated to optimize the performance of the immunosensor. As a result of the catalytic activity and biocompatibility of rGO-Au-Pd, the prepared CA242 immunosensor displayed a wide linear range of detection from 0.001 U/mL to 10,000 U/mL with a detection limit of 1.54 × 10−3 U/mL and a sensitivity of 4.24 μA (log10CCA242)−1. More importantly, the immunosensor exhibited satisfactory reproducibility and selectivity when detected CA242 in PBS or human serum. The results of our study provide a platform for the development of novel bioassays for use in early cancer diagnosis and promote the application of biosensing technology in the medical field.

show abstract

Multiple functional strategies for amplifying sensitivity of amperometric immunoassay for tumor markers: A review

Cited by 96 publications

References 127 publications

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

Conjugating immunoassays to mass spectrometry: Solutions to contemporary challenges in clinical diagnostics

A Label-Free Electrochemical Immunosensor for Detection of the Tumor Marker CA242 Based on Reduced Graphene Oxide-Gold-Palladium Nanocomposite

Contact Info

Product

Resources

About